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Abstract
Background: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL) is the most common form of hereditary stroke disorder caused by mutations in the NOTCH3 gene.
Although CADASIL scale is a widely used tool to screen clinically suspected CADASIL patients, the differential effects
of this scale in various populations remain unknown.
Methods: 92 CADASIL-like patients and 24 CADASIL patients were selected based on CADASIL scale and gene
tests. The clinical, genetic and radiological characteristics were analyzed.
Results: Based on the CADASIL scale, we first screened 116 suspected CADASIL patients, and detected 20 mutations in
24 CADASIL-patients (Specificity: 20.69 %). Surprisingly, we found that transient ischemic attack/stroke, migraine,
cognitive decline, psychiatric disturbances and early onset age in CADASIL scale showed no differences between the
CADASIL and the CADASIL-like patients (p > 0.05). Instead, recurrent cerebral ischemic events (58.33 %, p = 0.028) and
positive family histories (p < 0.05) were more frequently observed in CADASIL patients. Moreover, compared with
CADASIL-like patients (21.74 %), CADASIL patients demonstrated higher percentage of temporal pole involvements
(58.33 %, p = 0.001), but not the external capsule involvements (66.67 %, p = 0.602), in MRI imaging. Further, we found
that vascular risk factors could occur in both CADASIL patients and CADASIL-like patients, and therefore could not be
used as the markers to differentiate the two groups in our study (p > 0.05). By performing DSA analysis, we for the first
time identified dysplasia of cerebral blood vessels in CADASIL patients, which were detected more frequently in
CADASIL patients (41.67 %) in comparison with CADASIL-like patients (8.69 %, p <0.01).
Conclusion: Our data suggested that the efficacy of CADASIL scale to diagnose the disease varied with specific
populations. Recurrent cerebral ischemic events, temporal pole involvements (but not the external capsule) in MRI
imaging and dysplasia of cerebral blood vessels in DSA may be the new potential risk factors of the CADASIL scale
suitable for Chinese patients. Gene testing by encephalopathy gene panel is expected to improve the accuracy of
CADASIL differential diagnosis and increase the understanding of this disease in the future.
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Background
Cerebral autosomal dominant arteriopathy with subcor-
tical infarcts and leukoencephalopathy (CADASIL) is a
dominantly hereditary small-vessel disease caused by
mutations of the NOTCH3 gene in 19p13 [1, 2]. These
mutations occur mostly in the exons 2–24 of the
NOTCH3 gene encoding for the epidermal growth
factor-like (EGF-like) repeats, and lead to an odd num-
ber of cysteine residues with EGF-like region [2, 3]. This
disease is clinically characterized by migraine, recurrent
cerebrovascular events, psychiatric disturbance, and cog-
nitive impairment that eventually leading to dementia
and disability [1, 4]. The most typical pathological fea-
tures of CADASIL is the accumulation of granular
osmiophilic material (GOM) in the walls of small arter-
ies on ultrastructural examination [5]. In addition,
CADASIL patients usually demonstrated diffuse white-
matter changes in deep white matter, external capsules
and anterior pole of temporal lobes in the MRI imagings
[6–8].
The diagnosis of CADASIL is suspected when the pa-
tients showed typical clinical manifestations and demon-
strated diffuse white matter changes that frequently
extend to the temporal pole or lacunar infarcts in MRI
imaging. Unfortunately, although CADASIL is a single-
gene disorder of cerebral small vessel, the clinical char-
acteristics and neuroimaging manifestation varies even
within families [9, 10], increasing the difficulty in recog-
nizing the probands of CADASIL. GOM detection has
been considered as a more specific method to diagnose
CADASIL [4]. However, the inconsistent sensitivities re-
ported by different research groups [4, 11, 12] restricted
the usage of GOM detection to confirm the diagnosis of
CADASIL. Up till now, gene mutation analysis of
NOTCH3 still remains the golden standard to diagnose
the genetically inherited disease. And there are more
than 230 different mutations located in 20 different
exons reported in CADASIL patients [4, 13].
Nevertheless, NOTCH3 gene mutation analysis is still
costly and time-consuming [4, 14]. Therefore, it is rea-
sonable to pre-screen the suspected patients first to
avoid unnecessary gene mutation tests. The most fre-
quently used screening tool is the CADASIL scale estab-
lished by Francesca Pescini et.al. [15]. This scale was
reported to demonstrate a sensitivity of 96.7 and a speci-
ficity of 74.2 % in a pooled analysis of patients from dif-
ferent populations. However, with the increasing
identification of CADASIL worldwide [14, 16–18], accu-
mulating evidences from different studies suggested the
clinical and genomic characteristics of CADASIL varied
extensively among different regions [1, 2, 10, 14, 19–21].
Thus, it is necessary to further testify the available
CADASIL scale on more patients from different regions,
thereby evaluating the clinical efficacy of this scale in
various populations. In this study, to contribute to the
more specific characterizations of the genotype and the
phenotype of CADASIL, and more importantly, to refine
the pre-genetic screening tool, we investigated the clin-
ical manifestations, vascular risk factors, neuroimaging
characteristics, skin biopsies and NOTCH3 gene muta-
tion spectrums among 116 Chinese patients from Tongji
hospital in WuHan, China. Furthermore, we compared
the data between CADASIL and CADASIL-like patients
to identify new potential risk factor of CADASIL scale
suitable for Chinese patients.
Methods
Patients
From January 2009 to December 2014, we performed
NOTCH3 gene analysis in 144 inpatients who were
suspected with CADASIL at Tongji Hospital in China.
Then we retrospectively analysis the scores of CADASIL
scale and recruited 116 patients with a CADASIL scale
score ≥ 8 [6]. All studies were approved by the local ethics
committee, and informed consents were obtained from all
the participants. 24 of 116 patients were genetically
confirmed to be diagnosed as CADASIL with NOTCH3
mutation [3]. At the mean time, 92 patients who had no
mutation were grouped as CADASIL-like patients.
Clinical assessment
Specific clinical data of CADASIL were recorded in de-
tail including sex, age, age at onset, age at diagnosis,
onset-symptoms, family histories and the history of pres-
ence of vascular risk factors (including elevated blood
pressure, cigarette smoking, alcoholic intake, diabetes
mellitus, hyperhomocysteinanemia, heart disease).
Stroke and transient ischemic attack (TIA) were diag-
nosed according to the standard critiria [22]. Migraine
were classified according to the International Classifica-
tion Headache Disorders [23, 24]. Cognitive decline and
psychiatric disturbance were recorded if previous diag-
nosis has been made by a physician or if the patients ex-
ists cognitive decline, mood or behavior disorder
referred by themselves or their families. All patients
underwent magnetic resonance scans including T1, T2,
Flair inversion. Electron microscopy (EM) examination
for GOM by skin biopsy were performed in 14 of 24
CADASIL patients. The serum level of glutamic-pyruvic
transaminase (ALT), glutamic oxalacetic transaminase
(AST), cholesterol (Chol), triglyceride (TG), high-density
lipoprotein(HDL), low-density lipoprotein (LDL), homo-
cysteine, creatinine (Cr),N-terminal-brain natriuretic
peptide (NT-proBNP), cardical troponin-I (cTnI), and
fasting blood-glucose (FBG)were tested. The peripheral
blood vessels were examined by color Doppler Ultra-
soud, whlile the blood vessels of neck and head were
asessed by comupted tomography angiopraphy (CTA) or
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digital subtraction angiography (DSA). The average
diameter of the major blood vessels of the brain were
mesuared. When the artery of one side was signifcant
thinner than that of the other side, it is termed as
dysplasia.
Genetic study
Genomic DNA was extracted from peripheral blood sam-
ples using blood DNA extraction kit according to the
manufacturer’s recommendations (Qigen, Germany).
Polymerase chain reaction (PCR) was performed with
primers (comprising intron–exon boundaries) specific for
exons 3, 4, 11, 18 of the NOTCH3 gene firstly. Following
purification of PCR products, sequencing was performed
using the automated sequencer ABI 3730 (Applied Biosys-
tems, Foster City, CA, USA). If no mutations were present
in these exons, the remaining exons were also analysed.
Genetic analysis was performed at the Department of
Cardiology, Tongji Hospital, China.
Statistical analysis
Statistical analyses were performed using SPSS version
15.0 (SPSS, Inc., Chicago, Ill., USA). The results are
presented as means ± standard error of the mean. Stat-
istical analyses were performed with the unpaired t-test,
Fisher’s test or Mantel–Haenszel chi-square statistic
test. A P-value of <0.05 was taken as significant.
Results
Diagnosis of CADASIL and the mutation spectrum of
NOTCH3 gene
According to the CADASIL scale, we screened out
116 clinically suspected patients at Tongji Hospital
from January 2009 to December 2014. Among these
patients, we identified 92 NOTCH3 mutation negative
subjects (grouped as CADASIL-like patients, 40 men
and 52 women with a mean age at diagnosis of 57.83 ±
0.85 years), and 24 NOTCH3 mutation positive subjects
(grouped as CADASIL patients, 16 men and 8 women
with a mean age at the diagnosis of 54.67 ± 2.50 years),
from 24 different and unrelated families.
Our genetic analysis revealed 19 different missense
mutations and 1 deletion mutation in these patients,
12 of which have been reported in other researches
conducted in China [10, 14, 25], while 8 of which
were not (Fig. 1). All of these mutation are heterozy-
gous. NOTCH3 gene mutations were detected at the
exon 4 in 9 out of 24 of our patients (37.5), and at
the exon 3 in 6 patients (25 %). The other mutations
were located at exon 5 of patient No. 9, exon 6 of
patient No. 18, exon 10 of patient No.17, exon 11 of
patient No. 1, exon 18 of patient No. 4 and No. 22,
exon 20 of patient No. 20 and exon 22 of patient No.
8 and No.19. The majority of mutations in our study
were located in exon 4 and 3, followed by exon 18
and 22. But for CADASIL patients in Europe,
NOTCH3 mutations commonly occur in exon 4,
followed by exon 3, 5, and 6 [3, 18, 26, 27]. In
addition, of the above mutations, Notch 3 mutation
of p.Arg90Cys occured recurrently (4 of 24 CADASIL
patients) in our study, which was not detected in
Caucasian population [13].
Skin biopsies were taken from 14/24 CADASIL
patients to further confirm the diagnosis of CADASIL,
and GOM accumulation was detected in the basal layer
of vascular smooth muscle cells in 6/14 patients (Fig. 2).
Fig. 1 Schematic structure of the NOTCH3 gene mutations in the patients with CADASIL. The mutations which were not reported in previous
studies in the mainland of China are marked with asterisks
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Comparison of clinical manifestations between CADASIL
and CADASIL-like patients
Since CADASIL is often misdiagnosed due to the non-
specific clinical and radiological manifestations, it is neces-
sary to clarify the different phenotypes between CADASIL
patients and CADASIL-like patients. In this study, the
clinical characteristics of CADASIL and CADASIL-like
patients were compared.
In accordance with published data, as shown in
Table 1, the mean onset ages were similar between
the CADASIL group (52.67 ± 2.64 years old) and
CADASIL-like group (55.48 ± 0.88 years old, p =
Fig. 2 A typical image of GOM detection by skin biopsy from a 42-year-old patient with NOTCH3 p.Arg153Cys
Table 1 Clinical features of CADASIL and CADASIL-like patients





Age, years 55.08 ± 2.40 58.89 ± 0.86 0.072
Age at onset 52.67 ± 2.64 55.48 ± 0.88 0.200
Duration from first onset to diagnosis 2.00 ± 0.55 1.07 ± 0.25 0.104
History of vascular risk factors
Elevated blood pressure, % 33.33 76.09 0.000
Diabettes Mellitus, % 25.00 23.91 0.912
Cigarette smoking, % 58.33 47.83 0.359
Alcohol intake, % 25.00 23.91 0.912
Onset-manifestation
Migraine, % 33.33 23.91 0.348
acute cerebral events, % 66.67 58.70 0.477
psychiatric disturbances, % 25.00 13.04 0.261
cognitive impairment,% 41.67 41.30 0.974
Recurrent stroke, % 58.33 19.57 0.028
Presence of family history of migraine in at least 1 generation, % 25.00 4.35 0.005
Presence of family history of migrane in at least 2 generation, % 16.66 3.26 0.048
Presence of family history of acute cerebral events in at least 1 generation, % 41.66 8.70 0.000
Presence of family history of acute cerebral events in at least 2 generation, % 33.33 5.43 0.000
Presence of family history of psychiatric disturbance/cognitive impairment at least 1 generation, % 8.30 n.r -
Presence of family history of psychiatric disturbance/cognitive impairment in at least 2 generation, % n.r n.r -
CADASIL scale 16.2 ± 3.1 (10–22) 14.7 ± 2.5 (8–22) 0.047
CADASIL indicates cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy; ICH intracranial hemorrhage; n.r, not reported
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0.200). However, compared with CADASIL-like
patients, CADASIL patients demonstrated higher per-
centage of positive family histories (migraine and
acute cerebral events) with autosomal dominant in-
heritance (Table 1). In addition, CADASIL patients
showed higher percentage of recurrent ischemic
events than CADASIL-like patients (p = 0.028). The
scores of CADASIL scales are statistically higher in
CADASIL group than CADASIL-like group (p =
0.047).
On the other hand, inconsistent with published data [15],
the most common four onset symptoms of CADASIL scale
were similar between the CADASIL and the CADASIL-like
patients in our study (Table 1, p > 0.05), suggesting that
these four common onset symptoms only may not be good
risk factors of CADASIL scale for Chinese patients.
Comparison of Neuroimaging data between CADASIL and
CADASIL-like patients
To further testify the suitability of CADASIL scale, we
analyzed the typical neuroimaging features of CADASIL
patients (Fig. 3). The comparison of MRI scans showed
that the presence of leukoencephalopathy (91.67 % for
CADASIL group and 93.48 % for CADASIL-like group,
p = 0.760), subcortical and periventricular white matter
(75 for CADASIL group and 63.04 % for CADASIL-like
group, p = 0.272), capsula extrema involvement (66.67
for CADASIL group and 60.87 % for CADASIL-like
group, p = 0.602) were similar between two groups
(Fig. 3), which were consistent with previous report.
However, temporal pole involvement was significantly
more common in CADASIL patients (58.33 %) than in
CADASIL-like patients (21.74 %, p = 0.001), indicating
Fig. 3 T2-Flair magnetic resonance images from the same 42-year-old patient with NOTCH3 p.Arg153Cys showing diffuse white matter hyperintensities in
(a) bilateral centrum semiovale, (b) temporal pole and (c) pedunculus cerebellaris medius. (d) indicated the percentage of the positions involved (**p< 0.01)
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that temporal involvement may be a higher-risk factor
for CADASIL patients in our study.
Comparison of risk factors for cerebral vascular diseases
in CADASIL and CADASIL-like patients
Traditionally, it is believed that the pathological changes
of CADASIL are due to the mutations of NOTCH3 gene,
and the development of the CADASIL is not related to
other vascular disease such as atherosclerosis. Since both
of CADASIL patients and CADASIL-like patients have
similar clinical manifestations and diffused leukoence-
phalopathy in this study, it is necessary to investigate
whether cerebral-vascular risk factors could be used as
surrogate markers to differentiate CADASIL-like pa-
tients (i.e., who may be prone to be related to athero-
sclerosis) from CADASIL patients.
First, we investigated the common risk factors for
cerebral vascular disease in the natural history of these
patients. As is shown in Table 1, except for the rate of
elevated blood pressure in CADASIL patients (33.33 %)
was lower than that in CADASIL-like patients (76.09 %,
p < 0.01), rates of diabetes, cigarette smoking and alco-
holic intake showed no significant difference between
the two groups (p > 0.05, Table 1).
Second, laboratory tests relating to vascular disease (the
serum levels of AST, ALT, LDL, HDL, Cholesterol, TG,
homocysteine, proBNP, CTn-I, Cr and FBG) in CADASIL
and CADASIL-like patients were also analyzed. Interest-
ingly, hyperlipoproteinemia (33.33 % for CADASIL pa-
tients, 36.96 % for CADASIL like patients),
hyperhomocysteinemia (58.33 % for CADASIL patients,
67.39 % for CADASIL like patients), decreased HDL
(41.66 % for CADASIL patients, 65.21 % for CADASIL
like patients) and increased FBG (25 % for CADASIL pa-
tients, 28.26 % for CADASIL like patients) were observed
in both groups. Except for homocysteine (p = 0.043), all
the other items displayed similar levels between CADASIL
patients and CADASIL-like patients (p > 0.05, Table 2).
Further, both cerebral blood-vessels and the peripheral
blood-vessels were also assessed by Doppler Ultrasound,
DSA or CTA. Intracranial atherosclerosis was unexpect-
edly found in both CADASIL patients (12/24) and
CADASIL-like patients (64/92, p = 0.073), while occlu-
sion of cerebral arteries occurred in 2 CADASIL-like
patients. Of note, by performing DSA, we for the first
time found that CADASIL patients showed a higher
frequency of dysplasia of cerebral blood vessels (which is
defined as thinner than the blood vessels of the other
side) than CADASIL-like patients (Fig. 4, 10/24 in
CADASIL patients and 8/92 in CADASIL-like patients,
p = 0.000). Together, our data suggest that vascular risk
factors could occur in both CADASIL patients and
CADASIL-like patients and therefore could not be used
as markers to differentiate the two groups in our study.
Moreover, the existence of vascular risk factors and ab-
normality of intracranial arteries could not be used as
evidences to excluded the diagnosis of CADASIL.
Discussion
Genetic analysis of NOTCH3 gene remains as the
golden standard to diagnose CADASIL. However, due to
the heterogeneity of clinical manifestation and the non-
pathognomonic pattern of neuroimaging data, recogni-
tion of the disease before the genetic test is challenging.
As a pregenetic screening tool, the CADASIL scale
based on patients’ clinical characteristics and neuroimag-
ing data was recently developed to narrow down the po-
tential targets for further genetic evaluations [15, 28]. In
our study, we recruited 116 clinical suspected CADASIL
patients based on this scale in Tongji Hospital. Surpris-
ingly, only 24/116 (20.69 %) of them were genetically
confirmed as CADASIL and grouped as CADASIL pa-
tients, while other 92/116 (79.31 %) were grouped as
CADASIL-like patients. The prediction rate in our study
was not only lower than that based on Caucasian
patients, but also lower than the rate reported by other
Table 2 Evaluation of vascular risk factors
Laboratory tests CADASIL patients (n = 24) CADASIL-like patients (n = 92) P value
ALT, u/l 26.67 ± 4.96 27.16 ± 4.66 0.964
AST, u/l 25.70 ± 4.90 25.80 ± 2.36 0.986
Chol, mmol/l 3.48 ± 0.34 3.80 ± 0.13 0.330
TG, mmol/l 1.49 ± 0.094 1.50 ± 0.309 0.958
HDL, mmol/l 1.03 ± 0.094 0.99 ± 0.048 0.763
LDL, mmol/l 1.91 ± 0.253 2.40 ± 0.120 0.101
Cr, umol/l 85.38 ± 6.904 86.16 ± 6.577 0.959
homocysteine, umol/l 14.43 ± 1.947 18.8 ± 1.785 0.043
NT-proBNP, pg/ml 252.50 ± 185.114 406.79 ± 204.656 0.706
cTnI, ng/ml 0.02 ± 0.016 0.28 ± 0.275 0.623
FBG, mmol/l 5.85 ± 0.541 6.43 ± 0.467 0.640
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researches in China [10, 14, 29], who did not use this scale
for the diagnosis of CADASIL. The data suggested that
the current CADASIL scale was needed to be further
tested and refined, at least in our Chinese patients. Here,
to identify new potential risk factor for the refined CADA-
SIL scale, we compared the clinical manifestations and the
neuroimaging data between CADASIL and CADASIL-like
patients and analyzed the differences between them.
To our knowledge, our data for the first time demon-
strated that recurrent ischemic events, positive family
history and temporal pore involvement in MRI could be
used to further discriminate the CADASIL patients from
the CADASIL like patients (Table 1 and Fig. 3). And re-
current ischemic events should be considered as a new
risk factor in the diagnosis of CADASIL. In this re-
search, although the major first complaints of CADASIL
patients are still migraine, TIA/stroke, psychiatric dis-
turbance and cognitive impairment as indicated in other
research [6, 9, 29, 30], there are no statistical differences
between CADASIL and CADASIL-like patients (Table 1).
These findings support the idea that no clinical character-
istics of CADASIL is pathognomonic [13]. Instead, recur-
rent ischemic strokes were more frequently observed in
CADASIL patients than in CADASIL-like patients in our
study. One possible explanation for the phenomenon is
that GOM deposits in the medial layer of small penetrat-
ing arteries may promote the thickening of these vessels in
CADASIL patients [31]. And any subtle changes of cere-
bral blood-flow dynamic or small lesions of atherosclerotic
plaque, which may not be sufficient to induce stroke in
CADASIL-like patients, would cause recurrent small
cerebral infarcts by decreased blood perfusion [32]. Future
animal experiments are needed to testify the hypothesis.
Taken together, we believed that recurrent ischemic events
should be considered as a new risk factor for the diagnosis
of CADASIL, and be added into the CADASIL scale.
Of note, during the diagnosis of CADASIL, current
opinion pays lots of attention to the early onset age of
genetically inherited disease [1, 15]. For example, in
CADASIL scale, TIA/Stroke < 50 years old is given a
score of 2, while the recurrent ischemic events has not
been taken into consideration [15]. However in our in-
vestigation, the onset ages of CADASIL were relatively
older than that in the other studies conducted on Cauca-
sian population [6, 9], and showed no difference with
the onset ages in CADASIL-like patients. We speculated
that one reason is migraine was less frequently observed
as the first clinical manifestation in Chinese CADASIL
patients than in Caucasian patients, who usually showed
the symptom as early as 30 years old [1, 9]. On the other
hand, the early onset of the migraine symptoms may also
indicate the other potential genetic-related ischemic en-
cephalopathies, such as mitochondrial encephalomyopa-
thy, lactic-acidosis, stroke-like episodes (MELAS, caused
by MTTL1 mutation), familial hemiplegic migraine
(FHM, caused by CACNA1/ATP1A2/SCN1A mutations)
and Retinopathy, vascular, cerebral and renal involve-
ment, Raynaud and migraine attacks (HERNS, caused by
TREX1 mutation) [33]. To rule out these differential diagno-
sis of CADASIL, next generation sequencing (NGS)-based
gene panel test covering all the encephalopathy-related
gene mutations may be an useful diagnostic tool to gain
deeper understanding of these diseases in the future.
As an inherited single-gene disorder, it is commonly as-
sumed that the pathological changes of CADASIL are
mainly due to the effects of NOTCH3 gene mutations, but
not the effects of other factors, such as cerebral vascular
risk factors in the CADASIL-like patients [6, 28]. It has
been reported that, compared with CADASIL-like patients,
CADASIL patients had a lower percentage of vascular risk
factors [6, 8, 34]. And patients with large vessel infarctions
or artherosclerosis of intracranial vessels were even ex-
cluded from the CADAIL cohort in some studies [29].
Thus, we analyzed the differences of vascular risk factors
between CADASIL and CADASIL-like patients by history
taking and auxiliary tests, and evaluated whether these risk
Fig. 4 DSA image from the same 42-year-old patient with NOTCH3 p.Arg153Cys. showing angiodysplasia of left vertebral artery on the
(a) posteroanterior and (b) lateral view
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factors could help in differentiating the CADASIL patients
from the CADASIL-like patients. Unexpectedly, when
compared the history of vascular risk factors and the bio-
chemical items (Table 1 and Table 2) indicating the occur-
rence of white matter change and cerebral infarcts, there
were no significant differences between CADASIL and
CADASIL-like patients. Although CADASIL-like patients
demonstrated higher percentage of atherosclerosis (but not
significant when compared with CADASIL patients), we
still noticed 50 % patients of CADASIL had stenosis of
intracranial vessels and peripheral vessels, respectively.
This is much higher than that reported by Yin et al. in
other region of China [10]. Our data suggested that not
only the genetic effects of NOTCH3 gene mutations, but
also traditional vascular risk factors (or both of them)
might contribute to the pathological changes during the
development of CADASIL disease. In addition, in contrast
to previous findings that the pathological changes of
CADASIL mainly appeared in the medium sized and small
arterioles and occasionally in the vein (which could not be
detected in DSA imaging) [4, 12], we noticed more fre-
quent dysplasia of the major cerebral vessels in the DSA
imaging in the CADASIL patients than that in the CADA-
SIL like patients. The data indicated that the pathological
change of CADASIL could also influence the major cere-
bral artery in certain circumstances, and this characteristic
dysplasia of major vessels in DSA may be used as a new
portential risk factor for the refined CADASIL scale. To-
gether, our data revealed that the vascular risk factors and
abnormality of intracranial arteries should not be the rea-
sons to rule out the CADASIL diagnosis. And more future
researches are needed to establish a precise relationship of
the CADASIL phenotype with its genotype as well as the
environmental risk factors so that a personalized diagnosis
strategy could be designed. We believed that direct next
generation sequencing of gene panels that related to all the
known encephalopathies simultaneously instead of apply-
ing CADASIL scale may be the new orientation for
CADASIL diagnosis and research in the near future.
Conclusion
In conclusion, our data indicated that the screening
efficacy of CADASIL scale to identify the probands of
the genetic disease varied with different populations.
Recurrent cerebral ischemic events, temporal pole
involvements (but not the external capsule) in MRI
imaging and dysplasia of cerebral blood vessels in
DSA may be the new potential risk factors for the
CADASIL scale suitable for Chinese patients. Our
study provides new insights into the characterization
and specific diagnosis of the CADASIL disease, and
indicated the importance of gene panel test for accur-
ate diagnosis and research of a specific encephalop-
athy in the future.
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